The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology

Dobrynina, Larisa А.; Губанова, М. В.; Белопасова, А. В.; Baidina, E. V.; Afanasev, Maksim A.

doi:10.17116/jnevro202212202174

Z. nevrol. psikhiatr. im. S.S. Korsakova

2022

DOI: 10.17116/jnevro202212202174

|View full text |Cite

The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology

Larisa А. Dobrynina¹,

М. В. Губанова²,

А. В. Белопасова³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Belskaya,

Krasnikov,

Kiryanova

et al. 2024

RJTAO

View full text Add to dashboard Cite

Objective: to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice.Material and methods. In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezumab 225 mg subcutaneously monthly or 675 mg once (quarterly). We assessed changes in migraine attack intensity using a visual analogue scale (VAS), a reduction in the number of headache days per month by 50% or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability of fremanezumab.Results. The number of migraine days per month decreased by 50% or more in 52%, 63% and 70% of patients at weeks 4, 8 and 12, respectively. In 26% of patients, the number of days with headaches was reduced by 75% or more by the end of the study. On average, the number of days with migraine decreased by 11.6 per month, with monthly injections – by 12.6 per month (p<0.01). In patients who had negative experience with treatment with two or more groups of preventive therapies, the number of days with migraine was reduced by an average of 10.6 per month (p<0.01). The pain intensity according to VAS decreased from 9 to 5.7 points (p<0.001), the HIT-6 index decreased from 66 to 55 points (p<0.001). AEs occurred in 26% of cases, were transient and did not lead to discontinuation of treatment.Conclusion. The efficacy and safety of the use of fremanezumab in CM in real-world clinical practice has been demonstrated.

show abstract

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Belskaya,

Krasnikov,

Kiryanova

et al. 2024

RJTAO

View full text Add to dashboard Cite

show abstract

Efficiency of erenumab in neurologist’s real practice

Belskaya¹,

Kiryanova²,

Krasnikov³

et al. 2022

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab

Tkachenko¹,

Elkanov²,

Raevskaya³

et al. 2023

Rus. Jour. of Pain

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology

Cited by 3 publications

References 27 publications

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Efficiency of erenumab in neurologist’s real practice

Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab

Contact Info

Product

Resources

About